Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Idorsia is no longer continuing research into the use of ACT-539313 to treat binge eating disorders after failing to meet the primary endpoint in its latest trial.
Researchers released a study that has identified the first biochemical marker that could help detect babies more at risk of Sudden Infant Death Syndrome (SIDS) while they are alive.
Twist Bioscience and Astellas Pharma have entered into a collaboration to identify therapeutic antibodies to reduce tumor microenvironment-mediated immunosuppression.
Eisai and Biogen have completed the rolling submission of a Biologics License Application for lecanemab drug to the U.S. Food and Drug Administration.
CRISPR Therapeutics reported in its first-quarter financials, as of March 31, it had $2.221 billion in cash, cash equivalents and marketable securities to drive its progress.
MOMA stated that it plans to use the money to further develop product opportunities and advance a rich pipeline of precision oncology programs.
Three life sciences companies, ADC Therapeutics, Longeveron and Adimab, are undertaking leadership transitions with the announcements of new chief executive officers.
Pfizer made the splash of the young week Tuesday morning, inking an acquisition deal with New Haven, Connecticut-based Biohaven Pharma totaling $11.6 billion.
A recent study describes how researchers at the UK Research Institute at the University of Cambridge stumbled upon a potential target of dementia research.
In honor of World Lupus Day, BioSpace spoke with several companies making inroads in research and development for the treatment of the disease.
OncoResponse is developing an innovative cancer therapy based upon antibodies produced by patients to components in the tumor microenvironment that regulate the immune response.
bit.bio announced Monday that it has launched its Huntington’s Disease (HD) cell model to accelerate drug discovery and screening for patients with the disease.
PRESS RELEASES
Head-to-Head Study Highlights Rocbrutinib as the World’s First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations
Corporate Treasury Positioned with Cash and Liquid Equity Holdings to Seed, Incubate and Accelerate New and Existing Operations